Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 3 AMGN Why Amgen Stock Zoomed Nearly 12% Higher Today
May 3 AMGN Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
May 3 AMGN Analyst unveils Amgen stock price target after weight-loss drug data
May 3 AMGN Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending
May 3 AMGN Interest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise
May 3 AMGN William Blair, Barclays upgrade Amgen following GLP-1 drug update
May 3 AMGN Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
May 3 AMGN US STOCKS-Wall St rallies after soft jobs data allays rate jitters
May 3 AMGN Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
May 3 AMGN Weight-loss drug competition heats up. Is Wegovy in trouble?
May 3 AMGN Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript
May 3 AMGN Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers
May 3 AMGN US STOCKS-Wall St gains after soft jobs data allays rate jitters
May 3 AMGN Amgen stock rallies 13% on GLP-1 weight-loss drug update
May 3 AMGN Amgen Knocks Novo Nordisk's Ozempic Stock Rally
May 3 AMGN Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 3 AMGN Amgen surges over confidence in early obesity drug results
May 3 AMGN These Two Stocks Are Driving the Dow Friday
May 3 AMGN Stocks to Watch Friday: Apple, Amgen, Coinbase, Block
May 3 AMGN Amgen upgraded, Peloton downgraded: Wall Street's top analyst calls
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags